NVIV News Alert Design Source Inc (NVIV) 1.3900 12/25/2014 1

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Design Source Inc (NVIV) 1.3900 $NVIV

InVivo Therapeutics Announces FDA Approval to Expedite Enrollment for Ongoing Pilot Trial
Business Wire - Tue Dec 16, 7:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced approval by the U.S. Food and Drug Administration (FDA) for an expedited enrollment plan for the company's ongoing pilot trial of its investigational Neuro-Spinal Scaffold in patients with acute spinal cord injury. Under the new plan, barring significant safety issues, InVivo will submit two months of safety data to the FDA for the first subject enrolled in October, and will then open enrollment for the second subject in mid-January (about three months after the first subject was enrolled). Upon enrollment of the second subject, InVivo will submit to the FDA one month of safety data for that subject together with the previous subject's data; concurrent enrollment for the remaining three subjects will then begin (about two months after the second subject is enrolled). There will be no additional mandatory holds between enrollment of the final three subjects. This differs from the previous plan, which required a mandatory three-month hold between sequential enrollment of each of the five subjects.

InVivo Therapeutics Announces University of Pittsburgh Medical Center Presbyterian as New Clinical Trial Site for Neuro-Spinal Scaffold
Business Wire - Tue Nov 25, 7:01AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced the University of Pittsburgh Medical Center (UPMC) Presbyterian in Pittsburgh, PA as a clinical site in the company's ongoing IDE pilot study of its Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). UPMC is the largest non-governmental employer in Pennsylvania (with more than 62,000 employees) and operates more than 20 academic, community, and specialty hospitals and 400 outpatient sites. David Okonkwo, MD, PhD, is the Director of Neurotrauma and Director of Scoliosis and Spinal Deformity at UPMC Presbyterian and Associate Professor of Neurological Surgery and Clinical Director of the Brain Trauma Research Center at the University of Pittsburgh. Dr. Okonkwo will be the study's Principal Investigator at that site.

Can InVivo Therapeutics Holdings (NVIV) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 21, 7:35AM CST
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on NVIV’s earnings for the coming quarter and year.

InVivo Therapeutics Announces Oregon Health & Science University as Fifth Clinical Trial Site for Neuro-Spinal Scaffold
Business Wire - Fri Nov 21, 7:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the Oregon Health & Science University (OHSU) in Portland, OR is the fifth clinical site in the company's ongoing IDE pilot study of its Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). OHSU is a nationally prominent research university and Oregon's only public academic health center, seeing nearly one million patients every year. Ahmed Raslan, MD, an Assistant Professor of Neurological Surgery at OHSU, will be the study's Principal Investigator at that site.

Medical Device Makers Are Cheering After Latest Victory from GOP
ACCESSWIRE - Fri Nov 14, 10:15AM CST
CORAL GABLES, FL / ACCESSWIRE / November 14, 2014 / For Democrats, the "wounds" are still fresh. A new GOP senate now rules "the Hill" and amidst the fog of uncertainty for some key decisions has arisen one clear standout, which is Obamacare (The Affordable Care Act); more specifically the tax it placed on medical devices. See, the Affordable Care Act imposes a 2.3% excise tax on the sale of medical devices, which in most cases is one of the highest effective tax rates of nearly any industry in the world...and go figure, the US is the only country to impose such a tax on medical devices. In the end, it seems like it has come down to jobs or specifically the ones that have been lost because of the tax. In fact according to the Advanced Medical Technology Association, the Medical Device Tax has cost the industry about 14,000 jobs and prevented the creation of nearly 20,000 more. Now the rise for repeal has begun to echo on Capitol Hill from both parties and in turn, the market has reacted.

InVivo Therapeutics
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:56PM CST

STEM: 0.90 (+0.03), AST: 3.22 (+0.01), CUR: 2.70 (+0.07)

InVivo Therapeutics names Ann Merrifield to board
M2 - Wed Nov 12, 7:13AM CST
Biotechnology company InVivo Therapeutics Holdings (Other OTC:NVIV) disclosed on Tuesday the addition of Ann Merrifield to its board of directors.

Barrow Neurosurgeons Implant the World's First Scaffold into a Patient's Spinal Cord
PR Newswire - Tue Nov 11, 1:00PM CST
Performed last month, the surgery involves inserting a bioresorbable scaffolding implant to act as a bridge across the gap of the injured section of the cord in an attempt to help the spinal cord heal. This first case is part of a pilot study to measure the clinical safety of the implanted device developed by InVivo Therapeutics Holdings Corp. If proven successful, surgeons believe the new technique could become a standard protocol in the treatment of acute spinal cord injury.

InVivo Therapeutics Announces Appointment of Ann Merrifield to Its Board of Directors
Business Wire - Tue Nov 11, 7:00AM CST
InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Ann Merrifield to its Board of Directors. Ms. Merrifield most recently was President and Chief Executive Officer at PathoGenetix, a genomics company that developed and commercialized an automated system for rapid bacterial identification from complex samples.

InVivo Therapeutics beats by $0.01
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 5:13PM CST


InVivo Therapeutics Reports 2014 Third Quarter Financial Results and Business Update
Business Wire - Wed Nov 05, 3:30PM CST
InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the quarter ended September 30, 2014.

InVivo Therapeutics Receives FDA Approval to Broaden Inclusion Criteria and Add 14 Additional Sites (20 Total) for Ongoing Pilot Trial
Business Wire - Wed Oct 29, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the US Food and Drug Administration (FDA) has approved various changes to the protocol for the company's ongoing IDE pilot trial for acute spinal cord injury (SCI), including expanding the number of allowable clinical sites to 20 (previously six) and broadening the eligibility criteria. With this approval, the upper end of the age range has been increased from 55 to 65, the spinal cord injury level has been expanded from T3-T11 to T3-T12/L1, the enrollment window has been extended from 10 to 21 days post injury, and the Body Mass Index upper limit has been increased from 35 to 39.

InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc.
PR Newswire - Wed Oct 22, 6:30AM CDT
InVivo Therapeutics Holdings Corp. (OTCQB: NVIV) based in Cambridge, MA is revolutionizing spinal cord injury (SCI) treatment with their novel Neuro-Spinal Scaffold. This technique has been shown to outperform in tissue regrowth in the spinal cord area when cells are coupled with the scaffold. Made from an FDA approved polymer, the scaffold ultimately breaks down to water and carbon dioxide; making it harmless to the human body. NVIV has recently attracted significant investor attention with the announcement of the enrollment of the first subject in the pilot spinal cord injury trial and the approval of a fourth clinical site for the pilot study. The Company observed a 42% surge in their share price on a volume of 3,759,766 shares against an average daily volume of 355,474 shares on Oct 15, 2014 and 21.35% increase on 1,046,749 shares on Oct 20, 2014 pushing the share price above the 50-day SMA of $0.61. NVIV is still trading well below the 200-day SMA of $1.39; however with IRB approval for two additional clinical sights set to be announced in the coming weeks, a strong 2014 finish is expected for NVIV.

InVivo Therapeutics Announces Barnes-Jewish Hospital at Washington University as New Clinical Trial Site for Neuro-Spinal Scaffold
Business Wire - Mon Oct 20, 7:01AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the Barnes-Jewish Hospital at Washington University Medical Center in St. Louis, MO, is the fourth clinical site in the company's on-going IDE pilot study of its Neuro-Spinal Scaffold in patients with acute spinal cord injury (SCI). Barnes-Jewish Hospital is the largest regional trauma center in St. Louis and is one of the largest clinical spine care practices for the United States. Paul Santiago, MD, an Associate Professor of Neurological Surgery and Orthopedic Surgery at the Washington University School of Medicine in St. Louis, will be the study's Principal Investigator at the Barnes-Jewish Hospital.

InVivo, Neuralstem Treat Spinal Cord Injury Patients
Jason Napodano, CFA - at Seeking Alpha - Thu Oct 16, 12:53PM CDT

CUR: 2.70 (+0.07)

InVivo Therapeutics enrolls first acute spinal cord injury patient at St Joseph's Hospital and Medical Center trial
M2 - Thu Oct 16, 8:47AM CDT
Biotechnology company InVivo Therapeutics Holdings (other OTC:NVIV) disclosed on Wednesday the admission of the first subject in the pilot study of its Neuro-Spinal Scaffold for the treatment of complete traumatic spinal cord injury (SCI) in Phoenix, AZ.

InVivo Therapeutics Announces First Subject Enrolled in Pilot Spinal Cord Injury Trial
Business Wire - Wed Oct 15, 7:01AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced that the first subject has been enrolled in the pilot study of its Neuro-Spinal Scaffold for the treatment of complete traumatic spinal cord injury (SCI) at the Barrow Neurological Institute at St. Joseph's Hospital and Medical Center in Phoenix, AZ. The objective of the pilot study is to evaluate the safety and feasibility of the Neuro-Spinal Scaffold as well as to gather preliminary evidence of effectiveness.

InVivo Therapeutics to Exhibit at 2014 Congress of Neurological Surgeons Annual Meeting
Business Wire - Mon Oct 06, 7:00AM CDT
InVivo Therapeutics Holdings Corp. (NVIV) today announced the Company will be exhibiting at the 2014 Congress of Neurological Surgeons (CNS) Annual Meeting, to be held in Boston, MA October 18-22. The exhibit, InVivo's first at a major medical conference, will focus on strengthening and expanding the Company's neurosurgical network and increasing awareness about its ongoing clinical pilot study of the Neuro-Spinal Scaffold to treat acute spinal cord injury. InVivo will also host a social event in conjunction with the Congress, which is estimated to draw more than 3,000 attendees this year.

Deadline Monday: Levi & Korsinsky, LLP Reminds Investors of Class Action Against InVivo Therapeutics Holdings Corp. and Its Board of Directors and a Lead Plaintiff Deadline of October 6, 2014
Business Wire - Fri Oct 03, 11:06AM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased InVivo Therapeutics Holdings Corp. ("InVivo" or the "Company" (OTC:NVIV) securities between April 5, 2013 and August 26, 2013.

UPCOMING DEADLINE ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in InVivo Therapeutics Holdings Corp. to Contact the Firm Before the October 6, 2014 Lead Plaintiff Deadline in Class Action Lawsuit -- NVIV
GlobeNewswire - Thu Oct 02, 5:00AM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court of Massachusetts on behalf of purchasers of InVivo Therapeutics Holdings Corp. ("InVivo" or the "Company" (Other OTC:NVIV) common stock during the period between April 5, 2013 through August 26, 2013, inclusive (the "Class Period" .




Scroll down for more posts ▼

Top 10 Most Recent News Articles

SKINformed Bets on Skin Longevity Over Quick Fixes

Updated Category News Views 75

Wrinkle panic has been a very profitable racket for a long time, and SKINformed is trying to sidestep it. The physician-founded skincare brand is planting its flag on “SKINgevity,” a term it uses to describe long-term skin health rather than a frantic hunt for an overnight rewind. That is a sensible read on where beauty consumers appear to be headed: less appetite for...

Continue Reading
Minno Bets on Listener Kids to Build Premium Growth

Updated Category News Views 131

Children’s media rarely gets a clean strategic move, but this one comes pretty close. Minno has signed a worldwide, multi-year agreement making it the exclusive faith-based streaming home for Listener Kids’ video library, while commissioning 66 new episodes for its own service. For a company trying to build a serious Christian family-media business, that is more than...

Continue Reading
Colossal's Halloween Campaign Wins Top Communicator Honor

Updated Category News Views 76

A horror-themed fan competition putting money toward hospitalized children is not the usual awards-season material, which is precisely why Colossal's latest recognition lands with some weight. The Phoenix-based professional fundraiser received an Award of Excellence, the top honor at the 32nd annual Communicator Awards, for its Face of Halloween campaign in the Innovation...

Continue Reading
Specialized Metal Makers Become the New M&A Prize Again

Updated Category News Views 30

A forgotten heat-treatment line can suddenly be worth more than a shiny new mill when buyers realize nobody can duplicate its certifications, workforce, and customer approvals overnight. That is the basic truth sitting underneath BGL's Nov. 19, 2026 assessment of the U.S. metals market. The easy headline is consolidation. The useful takeaway is much narrower: specialized...

Continue Reading
HLRBO's Data-Heavy Rebuild Changes Hunting Lease Market

Updated Category News Views 137

A hunting lease used to begin with hearsay, blurry photos, and a whole lot of hoping. HLRBO is trying to drag that stubbornly analog process into a data-rich, phone-first marketplace, and frankly, it is about time. The company rebuilt its web and mobile platforms around parcel information, plain-language AI search, mobile lease completion, and its Land IQ™ scoring...

Continue Reading
Mindstream’s Jordan AI Campus Faces Its First Real Test

Updated Category News Views 39

Jordan’s AI ambitions just got attached to a very large gas meter. Mindstream Energy has unveiled a plan for an AI-ready data-center campus at Al-Risha in Mafraq Governorate, built around dedicated natural-gas generation rather than a conventional dependence on the utility grid. The headline number is 400 megawatts of eventual capacity. The number that matters first is...

Continue Reading
Jeff Stern Turns Travel Photography Into Full Attention

Updated Category News Views 57

A cancelled photography conference in March 2020 sent Jeff Stern toward the American Southwest, and that detour eventually became A Change of Scenery. Frankly, that origin has more grit than the usual polished creative-origin tale. While much of the world had stopped moving, Stern went alone, stood at White Pocket beneath a cobalt sky, and began reconsidering what he...

Continue Reading
Yangtze Documentary Frames a Decade of Economic Change

Updated Category News Views 13

A fish, a kilowatt-hour, a microchip, and a shipping container walk into the same economic story—well, not literally, thank goodness—and that is the unusual wager behind CCTV4’s upcoming Our Home, Our Yangtze. Announced in Beijing on November 19, 2026, the four-part documentary aims to recount a decade of change across the Yangtze River Economic Belt without leaning...

Continue Reading
DHC’s Ulta Rollout Gets a Useful Pricing Correction

Updated Category News Views 32

A face-wash price tag just became the most revealing part of DHC’s Ulta expansion. The company corrected an earlier announcement that had listed its new Deep Cleansing Face Wash at $31.50; the actual price is $19.00. That may sound like tiny housekeeping, and in the grand scheme it is, but consumer brands live or die on this kind of detail. A cleanser priced near $20...

Continue Reading
Full Truck Alliance Profits Surge as Revenue Slows

Updated Category News Views 122

A freight platform just delivered the kind of earnings math that makes investors sit up: sales barely jogged, while profit took off running. Full Truck Alliance’s third-quarter report is plainly strong on the surface, with net income up 49.0% year over year to RMB1.37 billion. Still, this is not a clean, uncomplicated growth story. The quality of the margin jump...

Continue Reading

Top 5 Most Recently Viewed Articles

OpenBench and ORIC Pharmaceuticals Forge a ground-breaking alliance

Updated Category News Views 102

OpenBench and ORIC Pharmaceuticals Team Up OpenBench, Inc., known for its innovative AI-driven discovery partnerships in the realm of small molecules, has announced a promising new collaboration with ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC). This partnership aims to utilize OpenBench's advanced success-driven discovery methods alongside its cutting-edge structure-based...

Continue Reading
IMUNON's Q3 2025 Update: Progress and Future Endeavors

Updated Category News Views 135

IMUNON Conference Call Announcement LAWRENCEVILLE, N.J. — IMUNON, Inc. (Nasdaq: IMNN), a pioneering clinical-stage biotechnology firm focusing on breakthrough DNA-mediated immunotherapy, is set to host a conference call at 11:00 a.m. ET on Thursday, November 13, 2025. This call will delve into the company’s financial results for the third quarter ending September 30,...

Continue Reading
Enhancements in Compliance Solutions Transforming MSP Landscape

Updated Category News Views 730

Exciting Upgrades to the Cyber Verify Compliance Platform Cyber Verify, a platform operated by MSPAlliance, has recently undergone significant enhancements aimed at revolutionizing the way Managed Service Providers (MSPs) approach compliance. With these new features, Cyber Verify is not just a tool, but a key partner for MSPs striving to achieve excellence in operational...

Continue Reading
Celebrating Latino Heritage: James Scott Farrin's Impact in 2024

Updated Category News Views 173

Supporting Latino and Hispanic Communities The Law Offices of James Scott Farrin has made remarkable strides in their commitment to supporting Latino and Hispanic communities. This year marks over a decade of their devoted involvement in various initiatives designed to uplift these communities and enhance their rights and opportunities. Sponsorship Highlights for 2024...

Continue Reading
AMTD's Dr. Calvin Choi Solidifies Leadership in HK

Updated Category News Views 20

Dr. Calvin Choi's Reappointment: A Strategic Move Out in the world of high stakes and corporate chess, Dr. Calvin Choi is making moves that echo far beyond the boardrooms. This guy isn't just resting on his laurels; his reappointment as President of the Hong Kong Island Federation spells serious business for AMTD IDEA (NYSE: AMTD), AMTD Digital (NYSE: HKD), and by...

Continue Reading